Divi’s Laboratories Ltd. is one of the largest generic active pharmaceutical ingredient manufacturers globally and has a successful track record of executing custom synthesis business for innovator customers.

Strong positioning of the company will help in monetising the growth opportunity in API and contract research and manufacturing services space given its stellar execution track record and being one of the preferred suppliers.

Further, recent and planned capex of approximately Rs 22 billion reinforces our view as Divis is known for expanding capacities with very high business visibility.



Source link

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *